William Blair Has Optimistic Outlook of NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.22). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. William Blair also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.88) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.33. The business had revenue of $29.18 million for the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.

A number of other research analysts have also commented on the company. Oppenheimer raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Friday. B. Riley began coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Thursday, March 13th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.92.

Nektar Therapeutics Trading Up 1.4 %

Nektar Therapeutics stock opened at $0.91 on Monday. The company has a market capitalization of $167.73 million, a price-to-earnings ratio of -1.08 and a beta of 0.65. The stock’s 50 day moving average is $0.88 and its 200-day moving average is $1.07. Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93.

Institutional Investors Weigh In On Nektar Therapeutics

Large investors have recently modified their holdings of the business. Nantahala Capital Management LLC increased its position in Nektar Therapeutics by 90.0% during the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock worth $7,263,000 after purchasing an additional 3,700,000 shares in the last quarter. Woodline Partners LP raised its position in shares of Nektar Therapeutics by 187.3% during the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after acquiring an additional 3,242,841 shares during the last quarter. Altium Capital Management LLC lifted its position in shares of Nektar Therapeutics by 26,172.0% in the 4th quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $2,790,000 after purchasing an additional 2,988,581 shares during the period. 22NW LP acquired a new position in Nektar Therapeutics in the fourth quarter valued at $2,038,000. Finally, Eventide Asset Management LLC lifted its stake in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after purchasing an additional 1,870,904 shares during the period. Institutional investors and hedge funds own 75.88% of the company’s stock.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. This trade represents a 8.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Zalevsky sold 51,115 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the sale, the insider now directly owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 118,591 shares of company stock valued at $112,525 over the last quarter. 3.71% of the stock is owned by corporate insiders.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.